泌尿生殖器治療薬の世界市場レポート 2025年

泌尿生殖器治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR2.9％で347億6,000万米ドルに成長します。予測される成長の原動力は、尿路感染症患者の継続的な増加、セクシュアル・ウェルネスに対する意識の高まり、ヘルスケア・インフラの改善、ホルモン補充療法の需要増加、経口避妊薬の採用拡大などです。この期間に予想される主な動向には、ドラッグ製剤およびデリバリー技術の革新、デジタルヘルスプラットフォームの利用、テクノロジーを活用した個別化治療アプローチ、生物学的療法の出現、精密医療技術の進歩などがあります。

泌尿生殖器疾患の有病率の増加は、泌尿生殖器治療薬市場の成長を促進すると予測されます。これらの疾患は、泌尿器や生殖器を含む泌尿生殖器系に影響を及ぼし、感染症、がん、構造的または機能的な問題などのさまざまな状態を包含します。これらの疾患の発生率の増加は、加齢に関連した変化が泌尿器系および生殖器系の健康問題の発生リスクを高めるため、高齢化人口に起因するところが大きいです。泌尿生殖器治療薬は、感染症、炎症、機能障害に対処することで、これらの疾患の管理に重要な役割を果たし、最終的には、生活の質を高める的を絞った便利な治療を通じて、患者の転帰を改善します。例えば、2024年4月の米国がん協会の報告によると、2022年には世界中で約2,000万人が新たにがんと診断され、970万人が死亡し、2050年には3,500万人に増加すると予測されています。その結果、泌尿生殖器疾患の有病率の増加が泌尿生殖器治療薬市場の拡大に寄与しています。

泌尿生殖器治療薬市場に参入している企業は、治療の利便性を向上させ、患者のアドヒアランスを高め、感染症と効果的に闘うために、経口抗生物質などの革新的な治療法の開発を優先しています。経口抗生物質は、細菌感染症を治療するために口から投与する薬剤です。2025年3月、英国の製薬会社GSK plcは、12歳以上の女性および女児の合併症のない尿路感染症の治療薬として、Blujepa（ゲポチダシン）のFDA承認を取得しました。この新規のファースト・イン・クラスの経口抗生物質は、DNAジャイレースとトポイソメラーゼIVという2つの必須酵素を標的として細菌のDNA複製を阻害することにより機能します。そのユニークな結合部位は抗生物質耐性を克服するのに役立ち、従来の抗生物質と比較して安全性と有効性が向上した、より標的を絞った治療を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の泌尿生殖器治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の泌尿生殖器治療薬市場：成長率分析
• 世界の泌尿生殖器治療薬市場の実績：規模と成長、2019年～2024年
• 世界の泌尿生殖器治療薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界の泌尿生殖器治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の泌尿生殖器治療薬市場：製品別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 泌尿器科
• ホルモン療法
• 婦人科
• 抗感染薬
• その他の製品
• 世界の泌尿生殖器治療薬市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 非経口
• 局所
• 世界の泌尿生殖器治療薬市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 尿路感染症（UTIS）
• 良性前立腺肥大症（BPH）
• 前立腺がん
• 過活動膀胱
• 膀胱がん
• その他の用途
• 世界の泌尿生殖器治療薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局
• 世界の泌尿生殖器治療薬市場、泌尿器科のサブセグメンテーション（種類別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 良性前立腺肥大症（BPH）治療薬
• 尿失禁薬
• 過活動膀胱（OAB）治療薬
• 尿路結石治療薬
• 勃起不全治療薬
• 世界の泌尿生殖器治療薬市場、ホルモン療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• エストロゲン療法
• プロゲスチン療法
• ゴナドトロピン放出ホルモン（GnRH）アゴニスト／アンタゴニスト
• アンドロゲン補充療法
• 選択的エストロゲン受容体モジュレーター（SERM）
• 世界の泌尿生殖器治療薬市場、婦人科のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 避妊薬
• 更年期ホルモン療法
• 不妊治療薬
• 子宮内膜症の薬
• 多嚢胞性卵巣症候群（PCOS）の治療薬
• 世界の泌尿生殖器治療薬市場、抗感染薬の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 尿路感染症（UTI）薬
• 性感染症（STI）薬
• 膣抗真菌薬
• 抗ウイルス薬
• 世界の泌尿生殖器治療薬市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 慢性骨盤痛の治療薬
• 膀胱がんの治療法
• 間質性膀胱炎の薬
• 骨盤臓器脱の治療薬
• 補助療法

第7章 地域別・国別分析

• 世界の泌尿生殖器治療薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の泌尿生殖器治療薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 泌尿生殖器治療薬市場：競合情勢
• 泌尿生殖器治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol Myers Squibb
• AstraZeneca plc
• Abbott Laboratories
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Ipsen Societe Anonyme
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Cipla Limited
• Hikma Pharmaceuticals Public Limited Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 泌尿生殖器治療薬市場2029年：新たな機会を提供する国
• 泌尿生殖器治療薬市場2029年：新たな機会を提供するセグメント
• 泌尿生殖器治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Genitourinary drugs are pharmaceutical agents used to treat conditions that impact the urinary and reproductive systems, including the kidneys, bladder, urethra, and genital organs. Their primary function is to address infections, manage overactive bladder, treat erectile dysfunction, alleviate urinary discomfort, and regulate hormonal activity. These medications aim to restore normal genitourinary functions and enhance patients' overall quality of life.

The key categories of genitourinary drugs include urologicals, hormonal therapies, gynecological treatments, anti-infectives, and other related products. Urologicals are a class of drugs specifically designed to manage disorders affecting the urinary system and male reproductive organs. These medications can be administered via oral, parenteral, or topical routes and are used to treat various conditions such as urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), prostate cancer, overactive bladder, bladder cancer, and more. Distribution channels for these drugs include hospital pharmacies, retail and drugstore pharmacies, as well as online pharmacies.

The genitourinary drugs market research report is one of a series of new reports from The Business Research Company that provides genitourinary drugs market statistics, including the genitourinary drugs industry global market size, regional shares, competitors with the genitourinary drugs market share, detailed genitourinary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the genitourinary drugs industry. This genitourinary drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genitourinary drugs market size has grown steadily in recent years. It will grow from $30.07 billion in 2024 to $31.02 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. This historical growth can be attributed to the rising incidence of urinary tract infections, a growing number of benign prostatic hyperplasia cases, increasing public awareness regarding sexual health, an aging global population, and a higher prevalence of chronic kidney diseases.

The genitourinary drugs market size is expected to see steady growth in the next few years. It will grow to $34.76 billion in 2029 at a compound annual growth rate (CAGR) of 2.9%. Forecasted growth will be driven by a continued rise in urinary tract infection cases, increasing awareness about sexual wellness, improvement in healthcare infrastructure, higher demand for hormone replacement therapies, and greater adoption of oral contraceptives. Key trends anticipated during this period include innovations in drug formulation and delivery technologies, the use of digital health platforms, personalized treatment approaches powered by technology, the emergence of biologic therapies, and progress in precision medicine techniques.

The increasing prevalence of genitourinary disorders is anticipated to drive the growth of the genitourinary drugs market. These disorders impact the genitourinary system, which includes the urinary and reproductive organs, and encompass a range of conditions such as infections, cancers, and structural or functional issues. The rising incidence of these conditions is largely attributed to the aging population, as age-related changes elevate the risk of developing urinary and reproductive health problems. Genitourinary drugs play a critical role in managing these disorders by addressing infections, inflammation, and dysfunction, ultimately improving patient outcomes through targeted, convenient treatments that enhance quality of life. For example, according to a report by the American Cancer Society in April 2024, approximately 20 million new cancer cases were diagnosed worldwide in 2022, resulting in 9.7 million deaths, with projections estimating a rise to 35 million cases by 2050. Consequently, the increasing prevalence of genitourinary disorders is contributing to the expansion of the genitourinary drugs market.

Companies operating in the genitourinary drugs market are prioritizing the development of innovative treatments such as oral antibiotics to improve therapeutic convenience, enhance patient adherence, and effectively combat infections. Oral antibiotics are medications administered by mouth to treat bacterial infections. In March 2025, GSK plc, a pharmaceutical company based in the UK, secured FDA approval for Blujepa (gepotidacin) to treat uncomplicated urinary tract infections in women and girls aged 12 years and older. This novel, first-in-class oral antibiotic functions by inhibiting bacterial DNA replication through the targeting of two essential enzymes-DNA gyrase and topoisomerase IV. Its unique binding sites help overcome antibiotic resistance, offering a more targeted treatment with improved safety and efficacy compared to traditional antibiotics.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This acquisition is intended to enhance Pfizer's cancer drug portfolio by integrating Seagen's advanced antibody-drug conjugate (ADC) technology with Pfizer's global capabilities and expertise. Seagen Inc., a biotechnology company based in the U.S., is recognized for its innovative genitourinary cancer therapies, including Padcev, which is used in the treatment of advanced bladder cancer.

Major players in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Societe Anonyme, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., and Asieris Pharmaceuticals.

North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genitourinary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genitourinary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genitourinary drugs market consists of sales of urinary acidifiers and alkalinizers, desmopressin, diuretics, urinary antispasmodics, anti-infectives, and hormone replacement therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genitourinary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genitourinary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for genitourinary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genitourinary drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Urologicals; Hormonal Therapy; Gynecological; Anti-Infectives; Other Products
• 2) By Route Of Administration: Oral; Parenteral; Topical
• 3) By Application: Urinary Tract Infections (UTIs); Benign Prostatic Hyperplasia (BPH); Prostate Cancer; Overactive Bladder; Bladder Cancer; Other Applications
• 4) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs; Urinary Incontinence Drugs; Overactive Bladder (OAB) Drugs; Urolithiasis (Kidney Stone) Drugs; Erectile Dysfunction Drugs
• 2) By Hormonal Therapy: Estrogen Therapy; Progestin Therapy; Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists; Androgen Replacement Therapy; Selective Estrogen Receptor Modulators (SERMs)
• 3) By Gynecological: Contraceptives; Menopausal Hormone Therapy; Fertility Drugs; Drugs for Endometriosis; Drugs for Polycystic Ovary Syndrome (PCOS)
• 4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs; Sexually Transmitted Infection (STI) Drugs; Vaginal Antifungals; Antivirals
• 5) By Other Products: Drugs for Chronic Pelvic Pain; Bladder Cancer Therapies; Interstitial Cystitis Drugs; Pelvic Organ Prolapse Treatment Drugs; Adjunctive Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Genitourinary Drugs Market Characteristics

3. Genitourinary Drugs Market Trends And Strategies

4. Genitourinary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genitourinary Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Genitourinary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Genitourinary Drugs Market Growth Rate Analysis
• 5.4. Global Genitourinary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Genitourinary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Genitourinary Drugs Total Addressable Market (TAM)

6. Genitourinary Drugs Market Segmentation

• 6.1. Global Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urologicals
• Hormonal Therapy
• Gynecological
• Anti-Infectives
• Other Products
• 6.2. Global Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• 6.3. Global Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infections (Utis)
• Benign Prostatic Hyperplasia (BPH)
• Prostate Cancer
• Overactive Bladder
• Bladder Cancer
• Other Applications
• 6.4. Global Genitourinary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Store And Retail Pharmacies
• Online Pharmacies
• 6.5. Global Genitourinary Drugs Market, Sub-Segmentation Of Urologicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benign Prostatic Hyperplasia (BPH) Drugs
• Urinary Incontinence Drugs
• Overactive Bladder (OAB) Drugs
• Urolithiasis Drugs
• Erectile Dysfunction Drugs
• 6.6. Global Genitourinary Drugs Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Progestin Therapy
• Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists
• Androgen Replacement Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• 6.7. Global Genitourinary Drugs Market, Sub-Segmentation Of Gynecological, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contraceptives
• Menopausal Hormone Therapy
• Fertility Drugs
• Drugs For Endometriosis
• Drugs For Polycystic Ovary Syndrome (PCOS)
• 6.8. Global Genitourinary Drugs Market, Sub-Segmentation Of Anti-Infectives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infection (UTI) Drugs
• Sexually Transmitted Infection (STI) Drugs
• Vaginal Antifungals
• Antivirals
• 6.9. Global Genitourinary Drugs Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs For Chronic Pelvic Pain
• Bladder Cancer Therapies
• Interstitial Cystitis Drugs
• Pelvic Organ Prolapse Treatment Drugs
• Adjunctive Therapies

7. Genitourinary Drugs Market Regional And Country Analysis

• 7.1. Global Genitourinary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Genitourinary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Genitourinary Drugs Market

• 8.1. Asia-Pacific Genitourinary Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Genitourinary Drugs Market

• 9.1. China Genitourinary Drugs Market Overview
• 9.2. China Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Genitourinary Drugs Market

• 10.1. India Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Genitourinary Drugs Market

• 11.1. Japan Genitourinary Drugs Market Overview
• 11.2. Japan Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Genitourinary Drugs Market

• 12.1. Australia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Genitourinary Drugs Market

• 13.1. Indonesia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Genitourinary Drugs Market

• 14.1. South Korea Genitourinary Drugs Market Overview
• 14.2. South Korea Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Genitourinary Drugs Market

• 15.1. Western Europe Genitourinary Drugs Market Overview
• 15.2. Western Europe Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Genitourinary Drugs Market

• 16.1. UK Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Genitourinary Drugs Market

• 17.1. Germany Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Genitourinary Drugs Market

• 18.1. France Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Genitourinary Drugs Market

• 19.1. Italy Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Genitourinary Drugs Market

• 20.1. Spain Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Genitourinary Drugs Market

• 21.1. Eastern Europe Genitourinary Drugs Market Overview
• 21.2. Eastern Europe Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Genitourinary Drugs Market

• 22.1. Russia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Genitourinary Drugs Market

• 23.1. North America Genitourinary Drugs Market Overview
• 23.2. North America Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Genitourinary Drugs Market

• 24.1. USA Genitourinary Drugs Market Overview
• 24.2. USA Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Genitourinary Drugs Market

• 25.1. Canada Genitourinary Drugs Market Overview
• 25.2. Canada Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Genitourinary Drugs Market

• 26.1. South America Genitourinary Drugs Market Overview
• 26.2. South America Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Genitourinary Drugs Market

• 27.1. Brazil Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Genitourinary Drugs Market

• 28.1. Middle East Genitourinary Drugs Market Overview
• 28.2. Middle East Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Genitourinary Drugs Market

• 29.1. Africa Genitourinary Drugs Market Overview
• 29.2. Africa Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Genitourinary Drugs Market Competitive Landscape And Company Profiles

• 30.1. Genitourinary Drugs Market Competitive Landscape
• 30.2. Genitourinary Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Genitourinary Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb
• 31.4. AstraZeneca plc
• 31.5. Abbott Laboratories
• 31.6. GSK plc
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Ipsen Societe Anonyme
• 31.12. Aurobindo Pharma Limited
• 31.13. Dr. Reddy's Laboratories Limited
• 31.14. Cipla Limited
• 31.15. Hikma Pharmaceuticals Public Limited Company

32. Global Genitourinary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genitourinary Drugs Market

34. Recent Developments In The Genitourinary Drugs Market

35. Genitourinary Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Genitourinary Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Genitourinary Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Genitourinary Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer